MA-BRIGHTCOVE-INC
14.7.2020 15:02:53 CEST | Business Wire | Press release
Brightcove Inc. (NASDAQ: BCOV), the world’s leading video technology platform, today announced the expansion of the Brightcove Global Partner Program , designed to further extend the power of video to reach global audiences quickly and easily. With a broad portfolio of partners specifically focused on media and enterprise organizations, the Brightcove Global Partner Program broadens the reach of Brightcove’s leading video technology solutions, which help fuel innovation and drive transformative business strategies with video.
Video is now a requirement to be a successful business. Brightcove’s Global Partner Program makes video technology readily available to organizations globally and enables them to implement it quickly through the channels that align best with their business models. By building a community of world-class partners, Brightcove is further democratizing the consumption of video, enabling companies around the world to bring their stories to viewers everywhere.
The newly-expanded program accommodates forward-thinking companies committed to ensuring the best experience for customers and end-users. The program consists of three types of partners:
- Referral Partners: Partners that refer their clients to Brightcove directly for a full video solution.
- Solution Partners: Systems integrators and resellers that build full video management solutions for their enterprise and media clients.
- Master License Partners: Partners that deliver Brightcove’s video technology and solutions as a managed service provider to clients of all sizes that demand the quality, choice, and support that Brightcove provides.
The Master License Partner program puts the full Brightcove platform within reach for all size clients. This new program allows Master License Partners to build upon their expertise, keeping them front and center to their clients, and now they are able to deliver world-class Brightcove video to their customers. Regardless of size, content type, and location, partners and clients alike are able to leverage leading video technology backed by Brightcove.
“As we continue to help enterprises broadcast their video content online, we want to ensure we’re offering them the most robust and premier video solutions available on the market,” said Blaise Kremer, Co-Founder, NovaStream. “Brightcove’s solutions allow the organizations we work with to enhance the delivery of their video content to their audiences, resulting in broader reach and exceptional viewing experiences. We are excited to be a part of Brightcove’s Partner Program, and look forward to helping more companies reap the benefits of video.”
"We are thrilled to be a part of Brightcove’s Global Partner Network and to help our customers stay at the forefront of the video revolution,” said Nuthapong Temsiripong, CEO, Digital Solution International Co., Ltd. “We have a long-standing relationship with Brightcove and have worked closely together to help media companies reduce their video streaming costs and increase revenue. As we move into the new partner program with additional enhancements and resources, we are excited to see our mutual customers continue to succeed with video.”
“Brightcove is committed to providing a strong global partner and channel ecosystem to support the demanding video needs for our customers,” said Lynn D. Tinney, Vice President, Global Partners at Brightcove. “Customers are our number one priority and we have enhanced our global partner program to enable them to deliver exceptional video experiences and exceed their audience’s expectations. Our partners offer services and solutions that are at the forefront of the digital transformation and with Brightcove as the core technology powering this network, we enable organizations that are serious about video to deliver secure and reliable content to viewers around the world.”
For more information on the Brightcove Global Partner Program, visit: https://www.brightcove.com/en/become-a-partner
About Brightcove Inc. (NASDAQ: BCOV)
We are the people behind the world’s leading video technology platform. With our award-winning technology and services, we help organizations in more than 70 countries meet business challenges and create strategic opportunities by inspiring, entertaining, and engaging their audiences through video.
Since Brightcove was established in 2004, we have consistently pushed boundaries to create a platform for people who are serious about video: one that is robust, scalable, and intuitive. Benefiting from a global infrastructure, unrivalled customer support, an extensive partner ecosystem, and relentless investment in R&D, Brightcove video sets the standard for professional grade video management, distribution, and monetization. To learn more, visit www.brightcove.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005607/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom